~~<i id='67397AE4CC'><strike id='67397AE4CC'><tt id='67397AE4CC'><pre id='67397AE4CC'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

hotspot

author：focus 2025-10-01 17:19:25 - browse：386

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Roivant's CEO is a star, but biotech's black hole persists

hotspot

entertainment

Wikipedia

knowledge

hotspot

entertainment

AdobeAlmostassoonasChatGPTwasreleasedtothepublic,doctorsbeganfocusingonhowtheycouldharnessartificial

WSS

How AI can help patients find reliable information about doctors

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

UnitedHealth, Optum discontinue NaviHealth name

Study on Amgen’s bispecific immunotherapy produces positive data

Health tech investors get more selective as pandemic boom fades

explore

hotspot

hotspot

George Santos makes 1st court appearance after pleading not guilty to 13 counts

J&J lung cancer data amount to new salvo against AstraZeneca

The high cost of giving birth even with insurance

Readout LOUD podcast: Live from the 2023 STAT Summit

Medical records are filled with copy

J&J lung cancer data amount to new salvo against AstraZeneca

Tori Bowie and the unacceptable rates of Black maternal death

N.Y. state detects polio case, first in the U.S. since 2013

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

entertainment

STAT Summit: Ending the crisis of Black deaths in the U.S.

STAT Readout: Friday, Oct. 20 biotech updates

Roivant's CEO is a star, but biotech's black hole persists

STAT Readout Newsletter: Biotech news today

Beach reads and more: STAT's 2023 summer book list

Is there really a nursing shortage in the U.S.?

Wikipedia

knowledge

hotspot

entertainment